latuda 37 mg
2care4 aps - lurasidonhydroklorid - tablett, filmdrasjert - 37 mg
latuda 74 mg
2care4 aps - lurasidonhydroklorid - tablett, filmdrasjert - 74 mg
rimstar
2care4 aps - rifampicin / isoniazid / pyrazinamid / etambutolhydroklorid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg / 275 mg
duoplavin
sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antithrombotic agents - duoplavin er indisert for sekundær forebygging av atherotrombotiske hendelser hos voksne pasienter som allerede tar både klopidogrel og acetylsalisylsyre (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. for ytterligere informasjon, vennligst referer til seksjon 5.
uromitexan 400 mg
baxter medical ab - mesna - tablett, filmdrasjert - 400 mg
uromitexan 100 mg/ ml
baxter medical ab - mesna - injeksjonsvæske, oppløsning - 100 mg/ ml
uromitexan 600 mg
baxter medical ab - mesna - tablett, filmdrasjert - 600 mg
ovugel
vetoquinol - triptorelin acetate - hypofysiske og hypotalamiske hormoner og analoger - pigs (sows for reproduction) - for the synchronisation of ovulation in weaned sows to enable a single fixed-time artificial insemination.
clopidogrel/acetylsalicylic acid zentiva (previously duocover)
sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antithrombotic agents - akutt koronar syndromemyocardial infarction.
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - mage-neoplasmer - antineoplastiske midler - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.